NeOnc Technologies Announces Topline Results From Its Phase 2A Portion Of NEO100-01 Study Of Intranasal NEO100 In Patients With Recurrent Or Progressive Glioma; Study Met Its Primary Endpoint; Will Request Type B Meeting With FDA

Loading news article.

NeOnc Technologies Announces Topline Results From Its Phase 2A Portion Of NEO100-01 Study Of Intranasal NEO100 In Patients With Recurrent Or Progressive Glioma; Study Met Its Primary Endpoint; Will Request Type B Meeting With FDA | WAPE

NeOnc Technologies Announces Topline Results From Its Phase 2A Portion Of NEO100-01 Study Of Intranasal NEO100 In Patients With Recurrent Or Progressive Glioma; Study Met Its Primary Endpoint; Will Request Type B Meeting With FDA

Article summary

Related companies

Comments —